Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Sutro Biopharma (STRO) Accumulated Depreciation & Amortization (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $27.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 43.75% to $27.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.4 million through Dec 2025, down 43.75% year-over-year, with the annual reading at $27.4 million for FY2025, 43.75% down from the prior year.
  • Accumulated Depreciation & Amortization hit $27.4 million in Q4 2025 for Sutro Biopharma, down from $48.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $48.6 million in Q4 2024 to a low of $27.4 million in Q4 2025.
  • Historically, Accumulated Depreciation & Amortization has averaged $37.9 million across 5 years, with a median of $37.9 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 15.34% in 2024 and later tumbled 43.75% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $33.4 million in 2021, then increased by 13.4% to $37.9 million in 2022, then increased by 11.23% to $42.2 million in 2023, then increased by 15.34% to $48.6 million in 2024, then crashed by 43.75% to $27.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for STRO at $27.4 million in Q4 2025, $48.6 million in Q4 2024, and $42.2 million in Q4 2023.